Brukinsa Gains Approval for Chronic Lymphocytic Leukemia
The approval was based on data from the phase 3 SEQUOIA and ALPINE studies in patients with CLL/SLL.
Chronic Lymphocytic Leukemia News
CHRONIC LYMPHOCYTIC LEUKEMIA ADVISOR
Chronic Lymphocytic Leukemia News
ASH 2022: New Findings in CLL
Research in patients with CLL showed that zanubrutinib can outperform ibrutinib, a triplet is effective for high-risk CLL, cell death may predict the depth of response, and a CAR T-cell therapy is likely not an option for CLL patients.
Zanubrutinib Outperforms Ibrutinib in Relapsed/Refractory CLL/SLL
Zanubrutinib prolongs progression-free survival, when compared with ibrutinib, in patients with relapsed/refractory CLL/SLL, a phase 3 trial suggests.
Zanubrutinib May Produce Better Outcomes Than Ibrutinib in Rel/Ref CLL, SLL
Zanubrutinib may produce superior outcomes to ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Lenalidomide Associated With Second Primary Malignancies in MM, Not Other Cancers
Lenalidomide increases the risk of developing a second primary malignancy in patients with multiple myeloma, a meta-analysis suggests.
Risk of VTE 6-Fold Higher in CLL/MBL Than in General Population
Patients with chronic lymphocytic leukemia or monoclonal B-cell lymphocytosis have an increased risk of venous thromboembolism, a study suggests.
Meta-Analysis Clarifies Risk of Cutaneous AEs Associated With PI3K Inhibitors
The incidence of cutaneous adverse events in cancer patients receiving PI3K inhibitors may be as high as 29%, a meta-analysis suggests.
Immune Responses to SARS-CoV-2 mRNA Vaccines Vary in Patients With Hematologic Malignancies
Researchers evaluated the anti-spike T-cell and antibody responses to SARS-CoV-2 mRNA vaccines in patients with B-cell malignancies in a real-world setting.
Zanubrutinib Appears Superior to Ibrutinib in Patients With Relapsed/Refractory CLL/SLL
Researchers sought to compare zanubrutinib with ibrutinib in patients with CLL/SLL.
Triplet Falls Short in Relapsed/Refractory Chronic Lymphocytic Leukemia
Combination acalabrutinib, obinutuzumab, and venetoclax did not meet the prespecified activity threshold in the CLL2-BAAG trial.
Long-Term Multicenter Study Underscores Role of 1L Cladribine in Hairy Cell Leukemia
Researchers sought to determine the long-term clinical experience of patients with HCL treated with frontline cladribine.
New Tablet Formulation of Calquence Approved for CLL, SLL, MCL
The approval was based on data from the phase 1 ELEVATE-PLUS trials, which showed that acalabrutinib 100 mg tablets were bioequivalent to the acalabrutinib 100 mg capsules.
Zanubrutinib Bests Bendamustine-Rituximab in Previously Untreated CLL/SLL
Zanubrutinib can improve progression-free survival, when compared with bendamustine-rituximab, in previously untreated CLL/SLL, a phase 3 trial suggests.
FDA Warns of Increased Side Effects, Death Risk With Duvelisib
The FDA recommends that health care providers evaluate the risks and benefits of continuing Copiktra vs prescribing an alternative therapy.
Venetoclax Plus Obinutuzumab May Improve PFS, Not OS in Chronic Lymphocytic Leukemia
Patients with previously untreated CLL had superior PFS with fixed duration venetoclax plus obinutuzumab, with or without ibrutinib.
Bacterial Coinfection Associated With Poor COVID-19 Outcomes in Chronic Lymphocytic Leukemia
Researchers sought to determine the case fatality rate in patients with CLL who were infected with SARS-CoV-2.
Eponyms in Oncology: Bence-Jones Protein
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake of the Bence-Jones protein.
Vaccine-Induced Responses to Omicron, Delta Impaired in Non-Hodgkin Lymphoma Patients
Of the NHL patients with neutralizing antibodies against the WA1/2020 SARS-CoV-2 strain, 70% had antibodies against the delta variant, and 33% had antibodies against the omicron variant.
Ukoniq Taken Off the Market; Pending Applications for CLL, SLL Withdrawn
TG Therapeutics has decided to take Ukoniq (umbralisib) off the market and withdraw pending applications for the drug.
Moderna COVID-19 Vaccine May Be More Effective in CLL Patients
Patients with CLL were significantly more likely to have an antibody response to the Moderna vaccine than to the Pfizer-BioNTech vaccine.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Chronic Lymphocytic Leukemia News
Loading... 
Loading...